Journal ArticleDOI
Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors
TLDR
There is a growing understanding of viral, host and environmental factors influencing disease progression, which ultimately could improve the management of chronic hepatitis B.About:
This article is published in Journal of Hepatology.The article was published on 2008-02-01. It has received 1172 citations till now. The article focuses on the topics: HBeAg & Hepatitis B.read more
Citations
More filters
Journal ArticleDOI
Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion
TL;DR: In randomized clinical studies involving patients with HBeAg‐positive CHB, treatment with pegylated interferon (PegIFN)‐ α is associated with higher and more durable H beAg seroconversion rates than are lamivudine and adefovir.
Journal ArticleDOI
Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies.
TL;DR: In hepatitis C patients, a sustained virological response to interferon-based therapies can reduce the rate of HCC development, even in patients with cirrhosis who experience histological regression of their liver disease.
Journal ArticleDOI
Development of algorithms based on serum markers and transient elastography for detecting significant fibrosis and cirrhosis in chronic hepatitis B patients: Significant reduction in liver biopsy.
TL;DR: To develop algorithms for detecting significant fibrosis and cirrhosis in chronic hepatitis B patients with the aim of reducing unwarranted liver biopsy.
Journal ArticleDOI
Association of cytokine gene polymorphisms and serum concentrations with the outcome of chronic hepatitis B
Simone Regina Souza da Silva Conde,Rosimar Neris Martins Feitosa,Felipe Bonfim Freitas,Renata B. Hermes,Samia Demachki,Marialva Tereza Ferreira de Araújo,Manoel do Carmo Pereira Soares,Ricardo Ishak,Antonio Carlos Rosário Vallinoto +8 more
TL;DR: Higher serum levels of IFN-γ and TGF-beta1 were associated with chronic hepatitis B, and lower serum levelsof IL-10 were found in patients with the active disease, suggesting a risk of the progressive disease.
Journal ArticleDOI
Hepatitis B virus infection and liver transplantation.
TL;DR: Improved posttransplant prophylaxis with antiviral and immunoglobulin therapy has led to a low risk of HBV re-infection and excellent outcomes after liver transplantation for HBV-related liver disease.
References
More filters
Journal ArticleDOI
Measuring inconsistency in meta-analyses
TL;DR: A new quantity is developed, I 2, which the authors believe gives a better measure of the consistency between trials in a meta-analysis, which is susceptible to the number of trials included in the meta- analysis.
Journal ArticleDOI
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.
Chien-Jen Chen,Hwai I. Yang,Jun Su,C.-L. Jen,San Lin You,Sheng-Nan Lu,Guan-Tarn Huang,Uchenna H. Iloeje +7 more
TL;DR: Elevated serum HBV DNA level (> or =10,000 copies/mL) is a strong risk predictor of hepatocellular carcinoma independent of HBeAg, serum alanine aminotransferase level, and liver cirrhosis.
Journal ArticleDOI
Chronic hepatitis B
Anna S. Lok,Brian J. McMahon +1 more
TL;DR: These guidelines have been written to assist physicians and other health care providers in the recognition, diagnosis, and management of patients chronically infected with the hepatitis B virus (HBV).
Journal ArticleDOI
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
TL;DR: HBV and HCV infections account for the majority of cirrhosis and primary liver cancer throughout most of the world, highlighting the need for programs to prevent new infections and provide medical management and treatment for those already infected.
Journal ArticleDOI
Hepatocellular carcinoma in cirrhosis: incidence and risk factors.
TL;DR: Further studies are needed to investigate other viral factors (eg, HBV genotype/mutant, occult HBV, HIV coinfection) and preventable or treatable comorbidities ( eg, obesity, diabetes) in the HCC risk in cirrhosis.